MEDICAL

Nordic Bioscience and Roche Diagnostics Strengthen Collaboration for Development of Biomarkers for Chronic Diseases

Nordic Bioscience | June 17, 2022

Nordic_Bio_science
Nordic Bioscience, a growing biomarker company, today announced the strengthening of its ongoing collaboration with Roche Diagnostics for the development of proprietary biomarkers involved in tissue breakdown and build-up.

Nordic Bioscience is a world leader in Extra Cellular Matrix (ECM) biomarker development that can provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.

Under the collaboration, Nordic Bioscience will transfer unique and proprietary blood-based biomarkers to Roche Diagnostics to be implemented on the automated COBAS platform. Nordic Bioscience's ECM biomarkers are unique and essential for all chronic diseases involving tissue fibrosis and inflammation. The collaboration will facilitate better clinical decisions in drug development and patient selection as well as enrichment for precision medicine and ultimately improve patient outcomes.

Nordic Biosciences has a long and successful collaboration with Roche Diagnostics. To date, two biomarkers have been commercialized and implemented on the Roche automated COBAS platform. Nordic Bioscience's fibrogenesis biomarker PRO-C3 has become a commonly used next-generation and noninvasive biomarker to quantify type III collagen formation which is highly relevant for NASH and other fibrotic diseases.

PRO-C6 quantifies type VI collagen formation, which is highly relevant for cardiovascular diseases and various cancer types. The FDA recently published a letter of support for further studies of PRO-C6 as a trial enrichment and patient selection biomarker in relation to Heart Failure with Preserved Ejection Fraction (HFpEF).

PRO-C3 and PRO-C6 are part of Nordic Bioscience's portfolio of ECM biomarkers which are being developed and commercialized both as research tools and in the future as diagnostic products. Both biomarkers have completed the technical development from manual ELISA to automated version on the COBAS platform. They are validated and currently running in routine in the CAP-accredited laboratory of Nordic Bioscience.

The collaboration with Roche Diagnostics is an important step for Nordic Bioscience in our efforts to help accelerate drug development. Having our biomarkers on the Roche Diagnostics' platform and our combined capabilities will secure global availability of our best ECM biomarkers. This also adds significant value to Nordic Bioscience offerings as we transform our biomarkers from tools used only in clinical development to globally available diagnostics products." 

Morten Karsdal Chief Executive Officer of Nordic Bioscience.

Nordic Bioscience has a long track record of research in ECM remodeling, which previously has resulted in the transfer of the FDA-approved bone biomarker CTX-I to the Roche COBAS platform. Nordic Bioscience has developed more than 125 ELISA biomarkers focusing on quantifying unique fragments of the ECM. These tools are used in all phases of drug development and for patient selection in various diseases.

About Nordic Bioscience
Nordic Bioscience is a Danish biomarker company headquartered in Herlev, Denmark. Nordic Bioscience is engaged in biomarker development using our unique neoepitope technology. We combine our expertise in biomarker development with preclinical and clinical research. This enables us to develop biomarkers that provide fast and objective decision-making for compound selection and development in clinical trials as well as provide value for patients in a diagnostic setting.

Spotlight

Trends in Data Analytics Headed for the Tax DepartmentTrends in Data Analytics Headed for the Tax DepartmentTrends in Data Analytics Headed for the Tax DepartmentTrends in Data Analytics Headed for the Tax Department

Spotlight

Trends in Data Analytics Headed for the Tax DepartmentTrends in Data Analytics Headed for the Tax DepartmentTrends in Data Analytics Headed for the Tax DepartmentTrends in Data Analytics Headed for the Tax Department

Related News

INDUSTRIAL IMPACT

SIGA Announces Oncology Collaboration with KaliVir Immunotherapeutics

SIGA Technologies Inc. | July 16, 2022

SIGA Technologies, Inc. a commercial-stage pharmaceutical company focused on the health security market, today announced a collaboration with KaliVir Immunotherapeutics to make TPOXX® available for use with KaliVir’s proprietary oncolytic vaccinia immunotherapy platform. This novel oncolytic platform includes multiple proprietary genetic modifications that can be combined to generate a unique oncolytic virus that has been optimized for systemic delivery and anti-tumor immune stimulation. Under this partnership, SIGA is providing its TPOXX oral capsules to support future clinical programs. “KaliVir is an innovator in the creation of oncolytic viral immunotherapies, and we are excited to enter into this collaboration with them. TPOXX is a powerful antiviral drug to vaccinia and allows the safe use of higher doses of vaccinia vectors; there is also the potential it could increase immunotherapeutic outcomes. This collaboration helps bring new levels of assurance to physicians, regulators, and especially patients receiving these promising investigational therapies.” Dr. Phil Gomez, CEO of SIGA “We are pleased to announce this collaboration with SIGA Technologies,” said Helena Chaye, Ph.D., J.D., CEO of KaliVir. “Pairing oncolytic immunotherapies with an effective antiviral agent is a critical part of the development of new treatments, and we look forward to enhancing our groundbreaking oncolytic immunotherapy programs with the support of SIGA’s TPOXX.” On July 13, 2018, the U.S. Food and Drug Administration (FDA) approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack. In preclinical studies, TPOXX has been shown to be active against most orthopoxviruses, including vaccinia The unique mechanism of action of TPOXX coupled with published efficacy in animal studies, make it an important addition to development programs focused on vaccinia-based cancer therapies. In 2020, SIGA entered into numerous collaborations, including a partnership with Turnstone Biologics to supply TPOXX to support Turnstone’s clinical oncolytic vaccinia immunotherapy programs. In 2021, SIGA entered into a preclinical research collaboration with Bioarchitech to investigate TPOXX enabling higher doses of vaccinia vectors when used in combination with Bioarchitech’s oncolytic vaccinia-based immunotherapy platform. ABOUT SIGA TECHNOLOGIES, INC. and TPOXX® SIGA Technologies, Inc. is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks (biodefense market), vaccines and therapies for emerging infectious diseases, and health preparedness. Our lead product is TPOXX®, also known as tecovirimat and ST-246®, an orally administered and IV formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the US maintains a supply of TPOXX under Project BioShield. The oral formulation of TPOXX was approved by the FDA for the treatment of smallpox in 2018. The full label is available by clicking here. Oral tecovirimat received approval from the European Medicines Agency (EMA) in 2022. The EMA approval includes labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The full label is available by clicking here. In September 2018, SIGA signed a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, for additional procurement and development related to both oral and intravenous formulations of TPOXX. ABOUT KALIVIR IMMUNOTHERAPEUTICS. KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, next-generation oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread (Vaccinia Enhanced Template “VET” Platform). VET™ platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients’ immune systems and modify the tumor microenvironment. KaliVir’s oncolytic product candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir is in the process of advancing multiple therapeutic candidates toward the clinic.

Read More

MEDICAL

Biosynth Carbosynth Further Expands Life Sciences Platform with Acquisition of Aalto Bio Reagents

Carbosynth | May 30, 2022

Biosynth Carbosynth (“Biosynth”), a supplier of critical materials to the life science industry, announces today the acquisition of Aalto Bio Reagents (“Aalto”), a leading developer and provider of biological materials to the in-vitro diagnostic (IVD) and vaccine development industry in the field of emerging disease. The acquisition represents a further milestone in Biosynth’s development, which broadens its capabilities and offering to the IVD industry. Aalto’s product portfolio includes an extensive range of proteins, antigens, antibodies, disease state human plasma and biospecimens used by the leading diagnostics and vaccine development companies around the world working on emerging diseases and disease variants. This acquisition marks the next phase of our ambitious journey to become a leading global supplier and partner to the biopharma and diagnostics industries. It allows us to offer an expanded range of products to our IVD customers including complex biochemicals, peptides and biological materials. We are pleased to welcome Aalto and its employees and look forward to working with them to continue to grow our offering to the diagnostics industry.” Dr. Urs Spitz, CEO and President of Biosynth. We are delighted to be joining forces with Biosynth, a world-renowned supplier with a broad portfolio of critical products and services across biopharma and diagnostics. Aalto’s industry leading products and key focus on emerging disease are an excellent fit with Biosynth’s products, and we see huge opportunities for the platform to be at the forefront of developing new innovative products and supplying our customers with an even greater scale and diversity of products they need to solve the diseases of the future.” Philip Noone, CEO of Aalto.

Read More

INDUSTRIAL IMPACT

ProPhase Labs to Announce Formation of a Subsidiary ProPhase BioPharma, Inc.

ProPhase Labs, Inc. | June 29, 2022

ProPhase Labs, Inc., a diversified biotech, genomics, and diagnostics company manufacturing homeopathic and health products, announced the formation of a new wholly-owned subsidiary, ProPhase BioPharma, Inc. (PBIO), for the development and licensing of new therapeutic compounds, drugs, and biotechnology. The subsidiary will be focused on advancements in technology across the biochemical industry and creating and developing new solutions that can transform the outcomes of healthcare. The company has also entered into a license agreement with a wholly-owned subsidiary of DSS, Inc., Global BioLife, Inc. (Global BioLife), for Equivir G and Equivir, proprietary compounds that were developed by Global Research and Discovery Group (GRDG). According to the terms of the contract, ProPhase Labs will be the only company that can develop and sell Equivir G and Equivir, globally. “We are thrilled to announce the formation of ProPhase BioPharma, our new wholly-owned subsidiary tasked with licensing and developing novel drugs, compounds, and biotechnology. We are equally pleased with our first licensing agreement for Equivir and Equivir G, which we believe have significant potential to improve human health outcomes worldwide.” Ted Karkus, ProPhase Lab’s Chief Executive Officer He further added, “We plan to pursue commercialization of Equivir as an OTC supplement, leveraging our distribution in over 40,000 Food Drug and Mass retail stores and online direct to consumer. We also look forward to applying to the FDA for an IND for Equivir G as a prescription antiviral.” Frank. D. Heuszel, Chief Executive Officer of DSS, said “We are excited to team up with ProPhase Labs, which will apply its nearly three decades of experience enhancing the health of the public to Equivir, which we believe to be a ground-breaking treatment that will positively impact health in the U.S. and globally.”

Read More